Company
Radiopharm Theranostics Ltd
ASX:RAD
Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).
101 stories · page 2 of 6
Radiopharm Theranostics rounds out entitlement offer with $1.2 million retail raise
The retail component brings RAD’s near $10 million entitlement offer to a close, with the institutional raise bringing A$5.5 million to the table.
Radiopharm Theranostics reaches agreement with ANSTO for supply of key isotope lutetium-177
The isotope will be used for the company's Phase I therapeutic trial in patients with non-small cell lung cancer.
Radiopharm Theranostics secures second supply of Actinium-225 from NorthStar Medical Radioisotopes
“It remains a priority for us to secure these key supply agreements, which allow us to continue with our clinical development unimpeded,” said RAD CEO and MD Riccardo Canevari.
Radiopharm Theranostics off to strong start in $10 million raise with institutional offer bringing in $5.5 million
“We are thrilled to have delivered a positive Phase 2 trial readout in brain mets which has a significant unmet clinical need just 11 months since IPO,” Radiopharm executive chairman Paul Hopper said.
Radiopharm Theranostics launches entitlement offer to raise up to $10 million
The company expects that the offer will provide a runway until at least the end of 2023, including for F 18 Pivalate PET that has returned positive Phase 2 data.